Priovant Therapeutics
Priovant Therapeutics Logo
About
Pipeline
Clinical Trials
News, Publications & Presentations
Careers
Contact
NEWS & PUBLICATIONS
4/2/2024
Priovant Therapeutics Announces Positive Phase 2 NEPTUNE Study Results for Brepocitinib in Non-Infectious Uveitis (NIU), Showing Strongest Efficacy Data in NIU Observed to Date
7/25/2022
Behind Pfizer’s New Quest to Target a 'Transformation' in Pharma
6/28/2022
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
6/28/2022
Roivant Unveils Latest Spinout as Pfizer Entrusts JAK1/TYK2 to Priovant
6/28/2022
Pfizer, Roivant Unveil Priovant with High Potential TYK2/JAK1 Inhibitor
5/23/2022
Use of Janus Kinase Inhibitors in Dermatomyositis: A Systematic Literature Review
PRESENTATIONS
4/15/2024
Introduction to Priovant
11/13/2023
Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
11/12/2023
Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis
11/11/2022
Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale